Biohaven (BHVN) Projected to Post Quarterly Earnings on Thursday

Biohaven (NYSE:BHVN) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) per share for the quarter.

Biohaven Stock Up 2.2 %

Shares of BHVN opened at $37.24 on Thursday. Biohaven has a 12-month low of $26.80 and a 12-month high of $62.21. The business’s fifty day moving average is $38.20 and its 200 day moving average is $42.75. The stock has a market cap of $3.77 billion, a P/E ratio of -3.98 and a beta of 1.28.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $59.00 price target on shares of Biohaven in a research report on Tuesday, December 17th. TD Cowen increased their price target on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price target (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Biohaven in a research report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price target for the company. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $63.15.

Insider Activity

In other Biohaven news, Director John W. Childs purchased 29,000 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the transaction, the director now owns 2,368,741 shares in the company, valued at $85,132,551.54. The trade was a 1.24 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.